This Aggressive Prostate Cancer Finally Has Targeted Treatment — AstraZeneca Wins FDA Nod

AstraZeneca received FDA approval for Truqap (capivasertib) in combination with abiraterone and prednisone for PTEN-deficient metastatic prostate cancer, marking the first targeted treatment for this patient population. The Phase III CAPItello-281 trial showed a 19% reduction in disease progression or death risk and a 7.5-month improvement in median radiographic progression-free survival. Additionally, Ultomiris received Priority Review for immunoglobulin A nephropathy treatment, with Phase 3 data showing a 46.6% reduction in proteinuria compared to 5.6% for placebo.